Amundi
RARE icon

Amundi’s Ultragenyx Pharmaceutical RARE Stock Holding History

Amundi’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,166
Closed -$318K – 2153
2026
Q1 		$318K Buy
+15,166
New +$342K ﹤0.01% 1723
2025
Q4 		– Sell
-99,161
Closed -$2.99M – 1885
2025
Q3 		$2.99M Hold
99,161
– – ﹤0.01% 1014
2025
Q2 		$3.91M Buy
99,161
+93,189
+1,560% +$3.36M ﹤0.01% 965
2025
Q1 		$210K Hold
5,972
– – ﹤0.01% 1668
2024
Q4 		$261K Hold
5,972
– – ﹤0.01% 1685
2024
Q3 		$318K Buy
5,972
+2,034
+52% +$104K ﹤0.01% 1536
2024
Q2 		$158K Sell
3,938
-15,712
-80% -$671K ﹤0.01% 1623
2024
Q1 		$852K Sell
19,650
-75,288
-79% -$3.55M ﹤0.01% 1316
2023
Q4 		$4.59M Sell
94,938
-33,054
-26% -$1.28M ﹤0.01% 1001
2023
Q3 		$4.3M Hold
127,992
– – ﹤0.01% 1015
2023
Q2 		$5.97M Buy
127,992
+90,062
+237% +$4.18M ﹤0.01% 946
2023
Q1 		$1.47M Sell
37,930
-714
-2% -$30.6K ﹤0.01% 1202
2022
Q4 		$1.61M Buy
38,644
+32,286
+508% +$1.27M ﹤0.01% 1234
2022
Q3 		$258K Buy
+6,358
New +$327K ﹤0.01% 1429

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Amundi's RARE Position: Q2 2026 in Review

Amundi sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 15,166 shares — an estimated $318K sold.

Amundi first reported a position in RARE in Q3 2022 and held it in 14 quarters. The position peaked at $5.97M in Q2 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Amundi reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Amundi sold 15,166 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $318K.
  • Amundi first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and held it in 14 quarters.
  • Amundi's Ultragenyx Pharmaceutical position peaked at $5.97M in Q2 2023.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.